MedTrace Logo

NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds

NCT02544061 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-11-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of NM-IL-12 relative to standard of care (SOC; control) in subjects with open surgical wounds.

Conditions

  • Colostomy Stoma

Interventions

BIOLOGICAL

NM-IL-12

single 12 µg unit subcutaneous (SC) dose of NM-IL-12

DRUG

Placebo

single subcutaneous dose

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Neumedicines Inc.

    lead INDUSTRY

Principal Investigators

  • Grant V Bochicchio, MD, MPH (GB) · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2017-10-31
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544061 on ClinicalTrials.gov